002422 科伦药业
午间休市 02-25 11:30:00
资讯
新帖
简况
科伦药业（002422）披露回购公司股份进展公告，2月3日股价上涨0.86%
证券之星 · 02-03
科伦药业（002422）披露回购公司股份进展公告，2月3日股价上涨0.86%
科伦药业：公司不涉及该病毒的药物
证券之星 · 01-28
科伦药业：公司不涉及该病毒的药物
科伦药业（002422）披露2026年度第一期科技创新债券发行结果，1月21日股价下跌1.23%
证券之星 · 01-21
科伦药业（002422）披露2026年度第一期科技创新债券发行结果，1月21日股价下跌1.23%
科伦药业涨6.19%，中国银河二个月前给出“买入”评级
证券之星 · 01-08
科伦药业涨6.19%，中国银河二个月前给出“买入”评级
科伦药业董事会通过股份回购方案，披露决议前十大股东持股情况
中金财经 · 01-06
科伦药业董事会通过股份回购方案，披露决议前十大股东持股情况
科伦药业(002422.SZ)拟斥5000万元至1亿元实施回购
智通财经 · 01-05
科伦药业(002422.SZ)拟斥5000万元至1亿元实施回购
科伦药业（002422）披露控股子公司拟实施2025年股份激励计划，12月11日股价下跌1.6%
证券之星 · 2025-12-11
科伦药业（002422）披露控股子公司拟实施2025年股份激励计划，12月11日股价下跌1.6%
科伦药业(002422.SZ)：公司5个品种药品纳入国家医保目录
智通财经 · 2025-12-08
科伦药业(002422.SZ)：公司5个品种药品纳入国家医保目录
科伦药业最新公告：科伦博泰与CrescentBiopharma建立战略合作伙伴关系涉及科伦博泰的SKB105和Crescent的CR-001两款候选药物
证券之星 · 2025-12-04
科伦药业最新公告：科伦博泰与CrescentBiopharma建立战略合作伙伴关系涉及科伦博泰的SKB105和Crescent的CR-001两款候选药物
Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项
美股速递 · 2025-12-04
Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项
Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款
美股速递 · 2025-12-04
Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款
科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法
美股速递 · 2025-12-04
科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法
科伦药业新注册《科伦悦签小程序系统1.0》等2个项目的软件著作权
证券之星 · 2025-11-15
科伦药业新注册《科伦悦签小程序系统1.0》等2个项目的软件著作权
科伦药业最新公告：棕榈酸帕利哌酮注射液获得药品注册批准为全球首个获批的每月给药一次的长效非典型抗精神病药
证券之星 · 2025-11-14
科伦药业最新公告：棕榈酸帕利哌酮注射液获得药品注册批准为全球首个获批的每月给药一次的长效非典型抗精神病药
科伦药业（002422）披露超短期融资券获准注册，11月12日股价上涨2.47%
证券之星 · 2025-11-12
科伦药业（002422）披露超短期融资券获准注册，11月12日股价上涨2.47%
科伦药业：通过互动易平台回应市场关切
证券之星 · 2025-11-10
科伦药业：通过互动易平台回应市场关切
四川科伦药业股份有限公司增持石四药集团(02005)112.8万股 每股作价约3.1港元
智通财经 · 2025-11-04
四川科伦药业股份有限公司增持石四药集团(02005)112.8万股 每股作价约3.1港元
科伦药业：目前根据《深圳证券交易所股票上市规则》相关规定
证券之星 · 2025-11-04
科伦药业：目前根据《深圳证券交易所股票上市规则》相关规定
科伦药业（002422）2025年三季报简析：净利润同比下降51.41%
证券之星 · 2025-11-01
科伦药业（002422）2025年三季报简析：净利润同比下降51.41%
科伦药业：历年分红累计超IPO融资总额
证券之星 · 2025-10-31
科伦药业：历年分红累计超IPO融资总额
加载更多
公司概况
公司名称：
四川科伦药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-06-03
主营业务：
四川科伦药业股份有限公司的主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等24种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。公司的主要产品是输液、非输液、研发项目、其他。
发行价格：
83.36
{"stockData":{"symbol":"002422","market":"SZ","secType":"STK","nameCN":"科伦药业","latestPrice":31.17,"timestamp":1771994871000,"preClose":31,"halted":0,"volume":3261200,"delay":0,"changeRate":0.0055,"floatShares":1306000000,"shares":1598000000,"eps":1.0423,"marketStatus":"午间休市","change":0.17,"latestTime":"02-25 11:30:00","open":31.05,"high":31.42,"low":30.93,"amount":102000000,"amplitude":0.0158,"askPrice":31.18,"askSize":7,"bidPrice":31.16,"bidSize":3,"shortable":0,"etf":0,"ttmEps":1.0423,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771995600000},"marketStatusCode":3,"adr":0,"adjPreClose":31,"symbolType":"stock","openAndCloseTimeList":[[1771983000000,1771990200000],[1771995600000,1772002800000]],"highLimit":34.1,"lowLimit":27.9,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1598053372,"isCdr":false,"pbRate":2.09,"roa":"--","peRate":29.905018,"roe":"5.18%","epsLYR":1.86,"committee":-0.169355,"marketValue":49811000000,"turnoverRate":0.0025,"status":0,"floatMarketCap":40704000000},"requestUrl":"/m/hq/s/002422","defaultTab":"news","newsList":[{"id":"2608551877","title":"科伦药业（002422）披露回购公司股份进展公告，2月3日股价上涨0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608551877","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608551877?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:27","pubTimestamp":1770128844,"startTime":"0","endTime":"0","summary":"截至2026年2月3日收盘，科伦药业报收于30.4元，较前一交易日上涨0.86%，最新总市值为485.81亿元。该股当日开盘30.36元，最高30.48元，最低30.01元，成交额达2.35亿元，换手率为0.6%。近日，科伦药业发布《关于回购公司股份进展的公告》。截至2026年1月31日，公司尚未实施回购。公司将根据市场情况推进回购，并及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300043248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0239","LU1934453819.USD","BK0060","002422","LU1979443071.USD","LU1064131003.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2606975124","title":"科伦药业：公司不涉及该病毒的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2606975124","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606975124?lang=zh_cn&edition=full","pubTime":"2026-01-28 08:12","pubTimestamp":1769559165,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)01月28日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，董秘，请问近期印度爆发尼帕病毒，公司有相关抗病毒药物吗？科伦药业回复：您好，公司不涉及该病毒的药物。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800006984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422","LU1064131003.USD","LU1064130708.USD","LU2148510915.USD","LU1934453819.USD","BK0239","BK0060","LU1979443071.USD"],"gpt_icon":0},{"id":"2605170537","title":"科伦药业（002422）披露2026年度第一期科技创新债券发行结果，1月21日股价下跌1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605170537","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605170537?lang=zh_cn&edition=full","pubTime":"2026-01-21 17:37","pubTimestamp":1768988220,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，科伦药业报收于32.25元，较前一交易日下跌1.23%，最新总市值为515.37亿元。该股当日开盘32.6元，最高32.66元，最低32.17元，成交额达3.67亿元，换手率为0.87%。近日，科伦药业发布《2026年度第一期科技创新债券发行结果的公告》。公告显示，四川科伦药业股份有限公司2026年度第一期科技创新债券已于2026年1月19日发行，募集资金于1月20日全额到账。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100029324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","LU1979443071.USD","LU1934453819.USD","LU1064130708.USD","BK0239","002422","BK0060"],"gpt_icon":0},{"id":"2601135664","title":"科伦药业涨6.19%，中国银河二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2601135664","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601135664?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:37","pubTimestamp":1767857866,"startTime":"0","endTime":"0","summary":"今日科伦药业涨6.19%，收盘报33.45元。2025年11月2日，中国银河研究员程培,孙怡发布了对科伦药业的研报《科伦药业2025年三季报业绩点评：业绩短期波动，创新产品持续兑现》，该研报对科伦药业给出“买入”评级。研报中预计公司2025-2027年归母净利润14.83/19.95/23.35亿元，同比增长-50%/35%/17%，当前股价对应2025-2027年PE为37/27/23倍，维持“推荐”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为97.37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800019286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422","601881"],"gpt_icon":0},{"id":"2601525218","title":"科伦药业董事会通过股份回购方案，披露决议前十大股东持股情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2601525218","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601525218?lang=zh_cn&edition=full","pubTime":"2026-01-06 10:16","pubTimestamp":1767665774,"startTime":"0","endTime":"0","summary":"中访网数据 四川科伦药业股份有限公司于2026年1月4日召开第八届董事会第十一次会议，审议通过了《关于回购公司股份方案的议案》。根据相关规定，该议案无需提交股东大会审议。公司于2026年1月6日披露了相关公告。截至该日，公司第一大股东为刘革新，持有379,128,280股，占总股本的23.72%；第二大股东为雅安市国有资产经营有限责任公司，持有96,983,174股，占比6.07%。根据公告，公司将在回购期限内根据市场情况择机实施回购。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260106/31918341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1064130708.USD","LU1064131003.USD","002422","LU1979443071.USD","BK0060","BK0239","LU1934453819.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2601887028","title":"科伦药业(002422.SZ)拟斥5000万元至1亿元实施回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2601887028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601887028?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:43","pubTimestamp":1767624203,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)公告，公司拟使用自有资金以集中竞价交易方式回购公司A股股份。回购资金总额不低于5000万元(含)，且不超过1亿元(含)。回购价格上限35元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU1979443071.USD","BK0060","LU1934453819.USD","BK0239","LU1064130708.USD","002422","LU1064131003.USD"],"gpt_icon":0},{"id":"2590259511","title":"科伦药业（002422）披露控股子公司拟实施2025年股份激励计划，12月11日股价下跌1.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590259511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590259511?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:10","pubTimestamp":1765462252,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，科伦药业报收于31.99元，较前一交易日下跌1.6%，最新总市值为511.22亿元。公司近日发布公告称，其控股子公司科伦博泰拟实施2025年股份激励计划，采用受限制股份单位形式，股份来源包括发行新H股、库存股或公开市场购入。该计划最高发行不超过350万股H股，约占总股本的1.5%。本次股份激励计划尚需经科伦博泰股东会批准及联交所批准。公告指出，该计划不会影响科伦药业的合并报表范围，亦不构成重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100041446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422","LU1934453819.USD","BK0060","LU2148510915.USD","BK0239","LU1064130708.USD","LU1979443071.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2589705339","title":"科伦药业(002422.SZ)：公司5个品种药品纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589705339","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589705339?lang=zh_cn&edition=full","pubTime":"2025-12-08 18:11","pubTimestamp":1765188683,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)公告，据国家医保局、人力资源社会保障部发布《关于印发<国家基本医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创新药品目录>(2025年)的通知》，公司及其控股子公司共计5个品种纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦药业(002422.SZ)：公司5个品种药品纳入国家医保目录","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002422","BK0239","LU2148510915.USD","LU1934453819.USD","LU1064131003.USD","BK0060","LU1979443071.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2588889788","title":"科伦药业最新公告：科伦博泰与CrescentBiopharma建立战略合作伙伴关系涉及科伦博泰的SKB105和Crescent的CR-001两款候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2588889788","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588889788?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:11","pubTimestamp":1764850275,"startTime":"0","endTime":"0","summary":"科伦药业公告称，公司控股子公司科伦博泰与Crescent Biopharma建立战略合作伙伴关系，共同开发和商业化肿瘤治疗手段。合作涉及两款候选药物：科伦博泰的SKB105和Crescent的CR-001。科伦博泰授予Crescent在美国、欧洲及大中华地区以外市场开发SKB105的独家权利，而Crescent授予科伦博泰在大中华地区开发CR-001的独家权利。科伦博泰将向Crescent收取8000万美元首付款，并有机会获得高达12.5亿美元的里程碑付款。同时，科伦博泰通过此次合作引入CR-001补充和加强了其差异化的肿瘤研发管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400035319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","BK0239","002422","LU1979443071.USD","LU1934453819.USD","LU1064131003.USD","BK0060"],"gpt_icon":0},{"id":"1115537632","title":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1115537632","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115537632?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847944,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","LU1934453819.USD","BK1161","LU1064131003.USD","BK0239","LU0196878994.USD","LU1979443071.USD","LU2148510915.USD","06990","002422","BK4139","LU1064130708.USD","CBIO"],"gpt_icon":0},{"id":"1126942018","title":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1126942018","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126942018?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847941,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","LU1064131003.USD","002422","LU0196878994.USD","LU1979443071.USD","BK0060","BK1161","BK0239","06990","BK4139","LU1934453819.USD","CBIO","LU2148510915.USD"],"gpt_icon":0},{"id":"1115079280","title":"科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1115079280","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115079280?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:30","pubTimestamp":1764847815,"startTime":"0","endTime":"0","summary":"科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","LU1064130708.USD","LU1934453819.USD","LU2148510915.USD","BK1161","BK4139","BK0239","002422","LU1979443071.USD","06990","CBIO","LU1064131003.USD","BK0060"],"gpt_icon":0},{"id":"2583177683","title":"科伦药业新注册《科伦悦签小程序系统1.0》等2个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2583177683","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583177683?lang=zh_cn&edition=full","pubTime":"2025-11-15 00:30","pubTimestamp":1763137838,"startTime":"0","endTime":"0","summary":"证券之星消息，近日科伦药业新注册了2个项目的软件著作权，包括《科伦悦签小程序系统1.0》、《科伦安行通小程序系统1.0》等。今年以来科伦药业新注册软件著作权4个，较去年同期增加了100%。通过天眼查大数据分析，四川科伦药业股份有限公司共对外投资了47家企业，参与招投标项目8624次；财产线索方面有商标信息1138条，专利信息2046条，著作权信息14条；此外企业还拥有行政许可1186个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111500000187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","LU1064130708.USD","LU1979443071.USD","BK0239","LU1064131003.USD","LU2148510915.USD","LU1934453819.USD","002422"],"gpt_icon":0},{"id":"2583083415","title":"科伦药业最新公告：棕榈酸帕利哌酮注射液获得药品注册批准为全球首个获批的每月给药一次的长效非典型抗精神病药","url":"https://stock-news.laohu8.com/highlight/detail?id=2583083415","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583083415?lang=zh_cn&edition=full","pubTime":"2025-11-14 19:39","pubTimestamp":1763120381,"startTime":"0","endTime":"0","summary":"科伦药业(002422.SZ)公告称，公司子公司湖南科伦制药有限公司的化学药品“棕榈酸帕利哌酮注射液”近日获得国家药品监督管理局的药品注册批准。该药品为全球首个获批的每月给药一次的长效非典型抗精神病药，具有提高患者用药依从性、减少疾病复发风险等优势。科伦药业在中枢神经疾病领域已有多个产品获批上市，本次棕榈酸帕利哌酮注射液的获批，将进一步提升公司在中枢神经领域的管线竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400035353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1979443071.USD","BK0060","LU1064131003.USD","LU1064130708.USD","LU2148510915.USD","LU1934453819.USD","002422","BK0239"],"gpt_icon":0},{"id":"2582377698","title":"科伦药业（002422）披露超短期融资券获准注册，11月12日股价上涨2.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582377698","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582377698?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:23","pubTimestamp":1762957401,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，科伦药业报收于33.13元，较前一交易日上涨2.47%，最新总市值为529.44亿元。该股当日开盘32.43元，最高33.5元，最低32.33元，成交额达5.09亿元，换手率为1.17%。公司董事会已审议通过发行非金融企业债务融资工具的议案，并经2024年年度股东大会批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422","BK0060","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","BK0239","LU1934453819.USD","LU1979443071.USD"],"gpt_icon":0},{"id":"2582825471","title":"科伦药业：通过互动易平台回应市场关切","url":"https://stock-news.laohu8.com/highlight/detail?id=2582825471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582825471?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:42","pubTimestamp":1762764130,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)11月10日在投资者关系平台上答复投资者关心的问题。投资者提问：科伦药业今年业绩大幅下滑，特别是第三季度业绩下滑的厉害，股价惨不忍睹 公司不该开业绩说明会，向广大投资者说明情况吗科伦药业回复：投资者您好，上市公司可根据具体情况确定是否召开季度业绩说明会。除业绩说明会外，公司通过互动易平台、投资者热线等渠道与广大投资者保持密切沟通，及时回应市场关切。未来，公司将进一步加强与投资者之间的交流、互动，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000020967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1979443071.USD","002422","LU1064130708.USD","LU1934453819.USD","LU2148510915.USD","LU1064131003.USD","BK0060","BK0239"],"gpt_icon":0},{"id":"2580780857","title":"四川科伦药业股份有限公司增持石四药集团(02005)112.8万股 每股作价约3.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580780857","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580780857?lang=zh_cn&edition=full","pubTime":"2025-11-04 19:20","pubTimestamp":1762255242,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，10月31日，四川科伦药业股份有限公司增持石四药集团(02005)112.8万股，每股作价3.0978港元，总金额为349.43万港元。增持后最新持股数目约为6.8亿股，最新持股比例为23.03%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","BK1191","BK0239","02005","LU1934453819.USD","BK0060","002422","LU1979443071.USD","LU2460026573.USD","LU1064131003.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2580200938","title":"科伦药业：目前根据《深圳证券交易所股票上市规则》相关规定","url":"https://stock-news.laohu8.com/highlight/detail?id=2580200938","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580200938?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:09","pubTimestamp":1762243748,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：三季度业绩下降70%，没有提前预告，是否违反交易所规定？如此简单的问题贵司都不懂吗？科伦药业回复：投资者您好，目前根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指南第1号——业务办理：第四部分4.1定期报告披露相关事宜（2025年修订）》的相关规定，上市公司自愿披露季度业绩预告，不再属于强制信息披露内容，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400023634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1934453819.USD","002422","LU1064131003.USD","LU1979443071.USD","LU2148510915.USD","LU1064130708.USD","399001","BK0060","BK0239"],"gpt_icon":0},{"id":"2580127734","title":"科伦药业（002422）2025年三季报简析：净利润同比下降51.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580127734","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580127734?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:41","pubTimestamp":1761950508,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期科伦药业发布2025年三季报。根据财报显示，科伦药业净利润同比下降51.41%。截至本报告期末，公司营业总收入132.77亿元，同比下降20.92%，归母净利润12.01亿元，同比下降51.41%。按单季度数据看，第三季度营业总收入41.93亿元，同比下降15.48%，第三季度归母净利润2.0亿元，同比下降70.18%。去年的净利率为15.41%，算上全部成本后，公司产品或服务的附加值高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422"],"gpt_icon":0},{"id":"2579458014","title":"科伦药业：历年分红累计超IPO融资总额","url":"https://stock-news.laohu8.com/highlight/detail?id=2579458014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579458014?lang=zh_cn&edition=full","pubTime":"2025-10-31 16:15","pubTimestamp":1761898519,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业10月31日在投资者关系平台上答复投资者关心的问题。公司将持续聚焦核心主业，不断提升经营业绩，为投资者创造价值。感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100032744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422","BK0239","LU2148510915.USD","LU1934453819.USD","LU1064131003.USD","BK0060","LU1979443071.USD","LU1064130708.USD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771994898546,"stockEarnings":[{"period":"1week","weight":-0.0177},{"period":"1month","weight":-0.037},{"period":"3month","weight":-0.1038},{"period":"6month","weight":-0.1475},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.0562}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":-0.0045},{"period":"3month","weight":0.0655},{"period":"6month","weight":0.0712},{"period":"1year","weight":0.2207},{"period":"ytd","weight":0.0374}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川科伦药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"37098人(较上一季度增加8.35%)","perCapita":"35200股","listingDate":"2010-06-03","address":"四川省成都市新都区新都卫星城工业开发区南二路","registeredCapital":"159805万元","survey":" 四川科伦药业股份有限公司的主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等24种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。公司的主要产品是输液、非输液、研发项目、其他。","listedPrice":83.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦药业,002422,科伦药业股票,科伦药业股票老虎,科伦药业股票老虎国际,科伦药业行情,科伦药业股票行情,科伦药业股价,科伦药业股市,科伦药业股票价格,科伦药业股票交易,科伦药业股票购买,科伦药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}